Lineage Cell Therapeutics, Inc. - FORM 10-K/A - EX-31 - EXHIBIT 31 - March 28, 2017

Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Lineage Cell Therapeutics, Inc.ex99_1.htm
EX-32 - EXHIBIT 32 - Lineage Cell Therapeutics, Inc.ex32.htm
EX-23.2 - EXHIBIT 23.2 - Lineage Cell Therapeutics, Inc.ex23_2.htm
10-K/A - BIOTIME, INC 10-K A 12-31-2016 - Lineage Cell Therapeutics, Inc.form10ka.htm
Exhibit 31

CERTIFICATIONS

I, Michael D. West, certify that:

1.          I have reviewed this annual report on Form 10-K/A of BioTime, Inc.

2.          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Date: March 28, 2017
   
/s/ Michael D. West
  
Michael D. West
  
Co-Chief Executive Officer
  
 

Exhibit 31

CERTIFICATIONS

I, Aditya Mohanty, certify that:

1.          I have reviewed this annual report on Form 10-K/A of BioTime, Inc.

2.          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Date: March 28, 2017
   
/s/ Aditya Mohanty
  
Aditya Mohanty
  
Co-Chief Executive Officer
  
 

Exhibit 31

CERTIFICATIONS

I, Russell Skibsted, certify that:

1.          I have reviewed this annual report on Form 10-K/A of BioTime, Inc.

2.          Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Date: March 28, 2017
   
/s/ Russell Skibsted
  
Russell Skibsted
  
Chief Financial Officer
  

 

Lineage Cell Therapeutics, Inc. Reports